Low Number of Donor Activating Killer Immunoglobulin-Like Receptors (KIR) Genes but not KIR-Ligand Mismatch Prevents Relapse and Improves Disease-Free Survival in Leukemia Patients After In Vivo T-Cell Depleted Unrelated Stem Cell Transplantation

Background. The effect of natural killer (NK) cell alloreactivity on outcome of unrelated stem cell transplantation (SCT) remains controversial. Killer immunoglobulin-like receptors (KIRs) recognize human leukocyte antigen C and B epitopes on target cells, thereby regulating NK cell activity. The KIR genes are polymorphic and two broad haplotypes exist: KIR-haplotype A mainly encode for inhibitory receptors and only for one activating (KIR2DS4), whereas the group B haplotype encodes more for activating KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 und KIR3DS1). Methods. The impact of KIR ligand mismatch on the number of activating and inhibitory donor KIR genes and on KIR-haplotype was studied on outcome of 142 patients with leukemia, who received standard myeloablative conditioning followed by in vivo T-cell depleted (ATG) unrelated SCT. Results. In a multivariate analysis KIR ligand mismatch had significantly higher treatment related mortality (RR 2.206, P=0.03), resulting in reduced overall (RR 2.015, P=0.02) and disease-free survival (RR 1.924, P=0.03). In contrast, SCT from donors with group A haplotype (P=0.003) or with low number of activating KIR genes (P=0.005) resulted in reduced relapse rate with improved disease-fee survival (P=0.04). This effect was seen only in acute myeloid leukemia/myelodysplastic syndrome and to a less extent in chronic myeloid leukemia. No effect was seen for acute lymphoblastic leukemia. Conclusions. After in vivo T-cell depleted (ATG) unrelated stem cell transplantation with donors carrying low number of activating KIR genes (group A KIR haplotype), the risk of relapse is reduced and resulted in a significantly better disease-free survival.

[1]  S. Forman,et al.  Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML , 2005, Bone Marrow Transplantation.

[2]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[3]  F. Christiansen,et al.  Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. , 2005, Tissue antigens.

[4]  F. Behm,et al.  Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors1 , 2005, The Journal of Immunology.

[5]  J. Beebe-Dimmer,et al.  Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. , 2005, Annual review of public health.

[6]  A. Elmaagacli,et al.  Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. , 2005, Blood.

[7]  R. Schots,et al.  A Defined Donor Activating Natural Killer Cell Receptor Phenotype Protects Against Leukemic Relapse after HLA-Identical Hematopoietic Stem Cell Transplantation. , 2004 .

[8]  H. Ljunggren,et al.  Increased Infection-Related Mortality in KIR-Ligand–Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation , 2004, Transplantation.

[9]  G. Ehninger,et al.  Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. , 2004, Blood.

[10]  F. Christiansen,et al.  The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. , 2004, Tissue antigens.

[11]  R. Handgretinger,et al.  Determinants of Antileukemia Effects of Allogeneic NK Cells 1 , 2004, The Journal of Immunology.

[12]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[13]  Daniel J Weisdorf,et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.

[14]  Markus Uhrberg,et al.  Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes , 2002, Immunogenetics.

[15]  N. Schleinitz,et al.  Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. , 2002, Human immunology.

[16]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[17]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[18]  C. Müller,et al.  How many probes are needed for HLA-DPB1 typing with sequence-specific oligonucleotide probes? A theoretical approach using computer simulation. , 1991, Human immunology.

[19]  D. Rowley,et al.  Dendritic cells that have interacted with antigen are targets for natural killer cells , 1985, The Journal of experimental medicine.